Software Equity Group

JANUARY 22, 2024

In this post, we’ll offer further insights into what’s driving the need for healthcare SaaS solutions and how business owners can capitalize on heightened activity in healthcare M&A. Few would disagree the American healthcare sector faces a great many challenges in terms of accessibility, affordability, and quality of care.

Healthcare 52

Healthcare M&A Valuation Medical 52

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Global Newswire by Notified: M&A

JULY 24, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 75

Pharmaceutical Securities 75

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 22, 2020

2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Global Newswire by Notified: M&A

JANUARY 12, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 45

Pharmaceutical Securities 45

Global Newswire by Notified: M&A

JANUARY 9, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 45

Pharmaceutical Securities 45

Global Newswire by Notified: M&A

JANUARY 3, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 45

Pharmaceutical Securities 45

Global Newswire by Notified: M&A

JANUARY 16, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 15, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 11, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 8, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 5, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 4, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

JANUARY 2, 2024

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 29, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 27, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 22, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 21, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 20, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 19, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 18, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 15, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 14, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 13, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 12, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 11, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 8, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 7, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 6, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 5, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 4, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

DECEMBER 1, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 29, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 28, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 27, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40

Global Newswire by Notified: M&A

NOVEMBER 24, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 40

Pharmaceutical Securities 40